^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine phosphorylase inhibitor

    Related drugs:
    1d
    A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. (PubMed, Discov Oncol)
    In this retrospective, real-world study, the two regimens demonstrated comparable disease control, and the bi-weekly regimen appeared to be better tolerated, representing a reasonable potential alternative. Nevertheless, these findings should be interpreted as exploratory, and future prospective studies are warranted.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    3d
    A single-arm, multicenter, open-label clinical study to evaluate the efficacy and safety of trifluridine/tipiracil combined with tislelizumab and bevacizumab in patients with third-line or later locally advanced unresectable or metastatic colorectal cancer (ChiCTR2500112562)
    P=N/A, N=57, Recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Lonsurf (trifluridine/tipiracil)
    3d
    Exploratory clinical study of fuquinitinib combined with TAS-102 as a second-line maintenance therapy for patients with metastatic colorectal cancer (ChiCTR2500112655)
    P4, N=40, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New P4 trial
    |
    RAS mutation
    |
    Lonsurf (trifluridine/tipiracil)
    3d
    Trifluridine-Tipiracil plus Fruquintinib vs Trifluridine-Tipiracil plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority trial (TAS-FUR) (ChiCTR2500112138)
    P4, N=236, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    3d
    Low-dose trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer: a multicenter, single-arm, phase 2 study (ChiCTR2500115479)
    P2, N=50, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    5d
    A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Anhui Provincial Cancer Hospital
    New trial
    |
    AiTan (rivoceranib) • Lonsurf (trifluridine/tipiracil)
    11d
    A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=464, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P3 trial
    |
    RAS mutation • RAS wild-type
    |
    Lonsurf (trifluridine/tipiracil)
    12d
    ALTAIR: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection (clinicaltrials.gov)
    P3, N=243, Completed, National Cancer Center Hospital East | Recruiting --> Completed
    Trial completion • Circulating tumor DNA
    |
    Signatera™
    |
    Lonsurf (trifluridine/tipiracil)
    22d
    Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer-a retrospective cohort study providing real-world survival and safety data from the United Kingdom. (PubMed, J Gastrointest Oncol)
    Toxicity is in line with that reported previously. Our data support the use of FTD/TPI in selected populations with aGC.
    Retrospective data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    Lonsurf (trifluridine/tipiracil)
    25d
    TriComB: Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (clinicaltrials.gov)
    P1/2, N=48, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    Avastin (bevacizumab) • capecitabine • Lonsurf (trifluridine/tipiracil)
    1m
    Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. (PubMed, J Natl Cancer Inst)
    In conclusion, no significant associations between KRAS-G12 and overall survival were found for TAS-102 or TAS-Bev. Further research is needed to assess the impact of these mutations on combined TAS-Bev therapy prior to any clinical application.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12 • KRAS G13
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)